Afrezza inhaled insulin meets primary endpoint in phase 3 pediatric diabetes trial – Contemporary Pediatrics
Afrezza inhaled insulin meets primary endpoint in phase 3 pediatric diabetes trial Contemporary Pediatrics Source link
Lilly’s efsitora meets primary endpoint in Phase 3 type 1 diabetes trial – World Pharmaceutical Frontiers
Lilly’s efsitora meets primary endpoint in Phase 3 type 1 diabetes trial World Pharmaceutical Frontiers Source link